Supplementation of antipsychotic treatment with sarcosine - G1yT1 inhibitor - causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia

Neuroscience Letters

Volumn 606, Issue , 2015, Pages 7-12

  Strzelecki, Dominik ^a   Podgórski, Michał ^b   Kałuzyńska, Olga ^a   Gawlik Kotelnicka, Oliwia ^a   Stefańczyk, Ludomir ^b   Kotlicka Antczak, Magdalena ^a   Gmitrowicz, Agnieszka ^b   Grzelak, Piotr ^b  

^a Maria Konopnicka Paediatric Centre   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

1H NMR spectroscopy; Glutamate; Hippocampus; NMDA receptor; Sarcosine; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PLACEBO; SARCOSINE; ASPARTIC ACID; GLYCINE TRANSPORTER; N-ACETYLASPARTATE; SLC6A9 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DSM-IV-TR; FEMALE; HIPPOCAMPUS; HUMAN; MALE; METABOLISM PARAMETERS; NEGATIVE SYNDROME; NEUROTRANSMISSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; CHOLINE; CREATINE; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIPPOCAMPUS; HUMANS; INOSITOL; MALE; MIDDLE AGED; SARCOSINE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84942012312     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.08.039     Document Type: Article

References (58)

1. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30:67-76.
2. Jääskeläinen E., Juola P., Hirvonen N., McGrath J.J., Saha S., Isohanni M., Veijola J., Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 2013, 39:1296-1306.
3. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia -therapeutic implications. Brain Res. Brain Res. Rev. 2000, 31:342-349.
4. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3:241-253.
5. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
6. Kantrowitz J., Javitt D.C. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr. Opin. Psychiatry 2012, 25:96-102.
7. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
8. Mattson D.T., Berk M., Lucas M.D. A neuropsychological study of prefrontal lobe function in the positive and negative subtypes of schizophrenia. J. Genet. Psychol. 1997, 158:487-494.
9. Qiu A., Tuan T.A., Woon P.S., Abdul-Rahman M.F., Graham S., Sim K. Hippocampal-cortical structural connectivity disruptions in schizophrenia: an integrated perspective from hippocampal shape, cortical thickness, and integrity of white matter bundles. Neuroimage 2010, 52:1181-1189.
10. Steen R.G., Hamer R.M., Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
11. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol. Psychiatry 2011, 69(5):495-503.
12. Kraguljac N.V., Reid M., White D., Jones R., den Hollander J., Lowman D., Lahti A.C. Neurometabolites in schizophrenia and bipolar disorder-a systematic review and meta-analysis. Psychiatry Res. 2012, 203:111-125.
13. 1H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
14. Rüsch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J., Olbrich H.M. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 2008, 99:155-163.
15. Kraguljac N.V., Reid M.A., White D.M., den Hollander J., Lahti A.C. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 2012, 37:2635-2642.
16. Bartha R., al-Semaan Y.M., Williamson P.C., Drost D.J., Malla A.K., Carr T.J., Densmore M., Canaran G., Neufeld R.W. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry 1999, 45:1403-1411.
17. van Elst L.T., Valerius G., Buchert M., Thiel T., Rusch N., Bubl E., Hennig J., Ebert D., Olbrich H.M. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 2005, 58:724-730.
18. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N.D., Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 2007, 62:1396-1404.
19. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
20. da Silva Alves F., Boot E., Schmitz N., Nederveen A., Vorstman J., Lavini C., Pouwels P.J., de Haan L., Linszen D., van Amelsvoort T. Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PloS One 2011, 6:e21685.
21. Szulc A., Galińska B., Tarasów E., Dzienis W., Kubas B., Konarzewska B., Walecki J., Alathiaki A.S., Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 2005, 38:214-219.
22. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri A.M. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 2007, 81:89-131.
23. 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage?. Brain Res. 2001, 892:166-175.
24. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol. Psychiatry 1998, 43:483-488.
25. Deicken R.F., Pegues M., Amend D. Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr. Res. 1999, 37:217-223.
26. 1H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:9-15.
27. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 1995, 25:1201-1209.
28. Maier M., Ron M.A. Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 1996, 22:5-17.
29. Weber-Fahr W., Ende G., Braus D.F., Bachert P., Soher B.J., Henn F.A., Büchel C. A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. Neuroimage 2002, 16:49-60.
30. Klär A.A., Ballmaier M., Leopold K., Häke I., Schaefer M., Brühl R., Schubert F., Gallinat J. Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study. Neuroimage 2010, 53:51-57.
31. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T.W., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 1996, 153:1554-1563.
32. Bertolino A., Kumra S., Callicott J.H., Mattay V.S., Lestz R.M., Jacobsen L., Barnett I.S., Duyn J.H., Frank J.A., Rapoport J.L., Weinberger D.R. Common pattern of cortical pathology of childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 1998, 155:1376-1383.
33. Bertolino A., Callicott J.H., Elman I., Mattay V.S., Tedeschi G., Frank J.A., Breier A., Weinberger D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry 1998, 43:641-648.
34. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology 1998, 18:1-9.
35. Bertolino A., Sciota D., Brudaglio F., Altamura M., Blasi G., Bellomo A., Antonucci N., Callicott J.H., Goldberg T.E., Scarabino T., Weinberger D.R., Nardini M. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry 2003, 160:483-489.
36. Callicott J.H., Egan M.F., Bertolino A., Mattay V.S., Langheim F.J.P., Frank J.A., Weinberger D.R. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol. Psychiatry 1998, 44:941-950.
37. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C., Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naïve patients with schizophrenia. Biol. Psychiatry 2003, 54:587-598.
38. Delamillieure P., Constans J.M., Fernandez J., Brazo P., Benali K., Courtheoux P., Thibaut F., Petit M., Dollfus S. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr. Bull. 2002, 28:329-339.
39. Kegeles L.S., Shungu D.C., Anjilvel S., Chan S., Ellis S.P., Xanthopoulos E., Malaspina D., Gorman J.M., Mann J.J., Laruelle M., Kaufmann C.A. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res 2000, 98:163-175.
40. Lutkenhoff E.S., van Erp T.G., Thomas M.A., Therman S., Manninen M., Huttunen M.O., Kaprio J., Lonnqvist J., O'Neill J., Cannon T.D. Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 2010, 15:308-318.
41. Olbrich H.M., Valerius G., Rusch N., Buchert M., Thiel T., Hennig J., Ebert D., Van Elst L.T. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry 2008, 9:59-63.
42. Bustillo J.R. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin. Neurosci. 2013, 15:329-337.
43. Kay S.R., Fiszbein A., Opfer L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13:261-276.
44. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 2010, 197:174-179.
45. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am. J. Psychiatry 2010, 167:1178-1193.
46. Guo X.-M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 2000, 157:1141-1149.
47. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
48. Vrajová M., Stastný F., Horácek J., Lochman J., Serý O., Peková S., Klaschka J., Höschl C. Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. Neurochem. Res. 2010, 35:994-1002.
49. Reif A., Schmitt A., Fritzen S., Lesch K.P. Neurogenesis and schizophrenia: dividing neurons in a divided mind?. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257:290-299.
50. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., Liu X.B., Yang C.H., Jordan J.D., Ma D.K., Liu C.Y., Ganesan S., Cheng H.J., Ming G.L., Lu B., Song H. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130:1146-1158.
51. Li B., Woo R.S., Mei L., Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
52. Varga V., Losonczy A., Zemelman B.V., Borhegyi Z., Nyiri G., Domonkos A., Hangya B., Holderith N., Magee J.C., Freund T.F. Fast synaptic subcortical control of hippocampal circuits. Science 2009, 326:449-453.
53. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31:234-242.
54. Cohen S.M., Tsien R.W., Goff D.C., Halassa M.M. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr. Res. 2015, http://dx.doi.org/10.1016/j.schres.2014.12.026.
55. Fox M.D., Raichle M.E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat. Neurosci. Rev. 2007, 8:700-711.
56. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38:950-957.
57. Szulc A., Konarzewska B., Galińska-Skok B., Łazarczyk J., Waszkiewicz N., Tarasów E., Milewski R., Walecki J. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci. Lett. 2013, 547:37-41.
58. Schwerk A., Alves F.D., Pouwels P.J., van Amelsvoort T. Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. J. Neurochem. 2014, 128:1-87.